生物製药第三方物流(3PL) 市场规模、份额和成长分析（按供应链、服务类型和地区划分）－产业预测 (2026-2033)

全球生物製药第三方物流(3PL) 市场规模预计到 2024 年将达到 1324.1 亿美元，到 2025 年将达到 1404.9 亿美元，到 2033 年将达到 2256.1 亿美元，预测期（2026-2033 年）的复合年增长率为 6.1%。

随着製药公司越来越多地将物流服务外包以更有效率地管理其分销网络，生物製药第三方物流(3PL) 市场正经历显着成长。 3PL 服务商透过先进的仓库管理系统，简化小分子药物的收货、订单履行和库存管理流程，从而为製药公司和医疗机构提供支援。这不仅降低了营运成本，防止产品供应中断，还有助于提高整体组织效率。推动市场成长的因素包括：强劲的销售业绩促使企业更加重视物流优化；生物相似药上市数量不断增加；以及对温控包装创新技术的需求，尤其是在疫情期间供应链中断之后。整体而言，生物製药 3PL 市场前景良好。

全球生物製药第三者物流(3PL) 市场驱动因素

对安全运输温控药品的高效物流解决方案的需求不断增长，预计将显着推动生物物流第三方物流 (3PL) 市场的发展。生物製药和生物相似药的扩张是推动市场成长的主要因素，因为这些药物的配送需要温控物流服务。此外，为降低营运成本，生产设施自动化程度的不断提高也进一步刺激了对 3PL 服务的需求。同时，慢性病盛行率的上升也导致生物製药需求增加，加速了生物製药第三方物流市场的扩张。

全球生物製药第三者物流(3PL) 市场限制因素

全球生物製药第三方物流(3PL) 市场面临严峻挑战，新兴经济体物流服务发展速度远落后于已开发地区。这种服务发展差距部分源自于生物製药 3PL 领域熟练劳动力短缺。合格人才的匮乏阻碍了该行业满足日益增长的物流服务需求并实现成长的能力。因此，劳动力短缺严重限制了全球医药 3PL 市场的扩张和效率，最终影响整个生物製药产业的供应链和服务交付。

全球生物製药第三方物流（3PL）市场趋势

全球生物製药第三方物流(3PL) 市场的一大趋势是向先进物流解决方案转型，这主要受附加价值服务需求成长的驱动。各公司正加大研发投入以提升自身能力，例如透过整合智慧感测器技术来监测运输过程中的环境状况。这项创新改进了敏感生物製药产品的追踪和处理，确保合规性和安全性。 DHL 等物流供应商正利用这些技术进步来优化其配送网络，并在一个优先考虑效率、可靠性和合规性的市场中获得竞争优势。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

全球生物製药第三方物流(3PL) 市场规模（按供应链和复合年增长率划分）（2026-2033 年）

• 低温运输物流
• 非低温运输物流

全球生物製药第三方物流(3PL) 市场规模（按服务类型和复合年增长率划分）（2026-2033 年）

• 运输
  • 空运货物
  • 海上运输
  • 陆运
• 仓储和存储
• 其他服务

全球生物製药第三方物流(3PL) 市场规模及复合年增长率 (2026-2033)

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• DHL（Germany）
• FedEx（USA）
• United Parcel Service（UPS）（USA）
• Kuehne+Nagel（Switzerland）
• DB Schenker（Germany）
• Agility（Kuwait）
• AmerisourceBergen Corporation（USA）
• McKesson Corporation（USA）
• Cardinal Health（USA）
• Thermo Fisher Scientific（USA）
• Cencora, Inc.（USA）
• EVERSANA（USA）
• Kerry Logistics Network Limited（Hong Kong）
• SF Express（China）
• XPO Logistics（USA）
• CEVA Logistics（Switzerland）
• Almac Group（UK）
• Cryoport, Inc.（USA）

结论与建议

Global Biopharmaceuticals Third Party Logistics 3pl Market size was valued at USD 132.41 Billion in 2024 and is poised to grow from USD 140.49 Billion in 2025 to USD 225.61 Billion by 2033, growing at a CAGR of 6.1% during the forecast period (2026-2033).

The market for biopharmaceutical third-party logistics (3PL) is experiencing significant growth due to the increasing trend of pharmaceutical companies outsourcing logistics services to handle their distribution networks more efficiently. 3PL providers support pharmaceutical and medical organizations by streamlining the receiving of small molecule pharmaceuticals, fulfilling orders, and managing inventory through advanced warehouse management systems. This not only helps reduce overhead costs and ensures an uninterrupted product supply but also enhances overall organizational efficiency. Factors driving market growth include a heightened focus on optimizing logistics amidst strong sales performances, the rise in biosimilar launches, and the need for innovations in temperature-controlled packaging, particularly following supply chain disruptions experienced during the pandemic. Overall, the biopharmaceutical 3PL market demonstrates a robust outlook.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biopharmaceuticals Third Party Logistics 3pl market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biopharmaceuticals Third Party Logistics 3pl Market Segments Analysis

Global Biopharmaceuticals Third Party Logistics 3pl Market is segmented by Supply Chain, Service Type and region. Based on Supply Chain, the market is segmented into Cold Chain Logistics and Non-cold Chain Logistics. Based on Service Type, the market is segmented into Transportation, Warehousing and Storage and Other Services. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biopharmaceuticals Third Party Logistics 3pl Market

The increasing need for efficient logistics solutions to safely transport temperature-sensitive medications is anticipated to significantly boost the biopharmaceutical third-party logistics (3PL) market. The expansion of biologics and biosimilars, which necessitate temperature-controlled logistics services for distribution, is a major contributor to this market's growth. Additionally, the rising implementation of automation in manufacturing facilities aims to lower operational costs and is further driving the demand for 3PL services. Moreover, the growing prevalence of chronic illnesses has led to a heightened requirement for biologics, which in turn accelerates the expansion of the biopharmaceutical third-party logistics market.

Restraints in the Global Biopharmaceuticals Third Party Logistics 3pl Market

The global biopharmaceutical third-party logistics (3PL) market faces significant challenges due to the slower development of logistics services in emerging economies compared to those in developed regions. This disparity in service advancement is partly driven by a scarcity of skilled labor within the biopharmaceutical 3PL sector. The lack of qualified professionals hinders the industry's ability to grow and adapt to the increasing demand for logistics services. Consequently, these workforce limitations pose a considerable restraint on the expansion and efficiency of the global pharmaceutical 3PL market, ultimately affecting the overall supply chain and service delivery within the biopharmaceutical industry.

Market Trends of the Global Biopharmaceuticals Third Party Logistics 3pl Market

The Global Biopharmaceuticals Third Party Logistics (3PL) market is witnessing a significant trend towards advanced logistical solutions driven by escalating demand for value-added services. Companies are increasingly investing in research and development to enhance their capabilities, particularly through the integration of smart sensor technology that monitors ambient conditions during transportation. This innovation allows for improved tracking and handling of sensitive biopharmaceutical products, thereby ensuring compliance and safety. Logistics providers like DHL are leveraging these technological advancements to optimize their distribution networks, positioning themselves competitively in a market that emphasizes efficiency, reliability, and regulatory adherence.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Biopharmaceuticals Third Party Logistics 3pl Market Size by Supply Chain & CAGR (2026-2033)

• Market Overview
• Cold Chain Logistics
• Non-cold Chain Logistics

Global Biopharmaceuticals Third Party Logistics 3pl Market Size by Service Type & CAGR (2026-2033)

• Market Overview
• Transportation
  • Air Freight
  • Sea Freight
  • Overland
• Warehousing and Storage
• Other Services

Global Biopharmaceuticals Third Party Logistics 3pl Market Size & CAGR (2026-2033)

• North America (Supply Chain, Service Type)
  • US
  • Canada
• Europe (Supply Chain, Service Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Supply Chain, Service Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Supply Chain, Service Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Supply Chain, Service Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• DHL (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FedEx (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United Parcel Service (UPS) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kuehne+Nagel (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DB Schenker (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agility (Kuwait)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AmerisourceBergen Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• McKesson Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cencora, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EVERSANA (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kerry Logistics Network Limited (Hong Kong)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SF Express (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• XPO Logistics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CEVA Logistics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almac Group (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cryoport, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations